Bone Marrow Diseases  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

   Remove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bone Marrow Diseases
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Checkmark In 2nd line CML chronic phase pts
Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts
Active, not recruiting
3
90
Japan, US, Europe, RoW
Nilotinib, Imatinib
Novartis Pharmaceuticals
Myelogenous Leukemia, Chronic
10/18
10/18

Download Options